Close up of older male teenager with visible acne. Close up of older male teenager with visible acne.

TWYNEO cream

Fight acne fast

with the 2-in-1 that’s never been done

Microencapsulation technology

The rapid efficacy you demand and tolerability they deserve.1-4

Not an actual patient.
For Patients 9 and Up1

Acne's first-ever
.1% tretinoin & 3% BPO 2-in-11,2

The once-daily cream that finally unites 2 proven ingredients for a never-before-seen fixed-dose combination. Using microencapsulation technology, TWYNEO cream helps patients stay on track with rapid results and tolerability with transient effects over time.1-4

Photo of TWYNEO cream on someone's hand
Microencapsulation

Combination meets innovation2

Explore Further
Microencapsulation logo
Younger male teenager with visible acne smiling confidently at camera.
Not an actual patient.
Results

Potent doses for rapid results3*

See Data
Safety

Favorable tolerability1,3,4

Learn More
Male teenager smiling at the camera
Not an actual patient.
Older female teenager smiling confidently at camera.
Not an actual patient.
Satisfaction

High rates of patient-reported satisfaction3,4

View Results
Image of the CareConnect Savings card.

Don't let your patients break the bank fighting breakouts

Discover Savings

BPO=benzoyl peroxide.

*

Noninflammatory lesion reduction at Week 2.3,4

References: 1. TWYNEO (tretinoin and benzoyl peroxide) cream, 0.1%/3% [Prescribing Information]. Fort Worth, TX: Mayne Pharma; July 2021. 2. Sol-Gel Technologies Ltd. Sol-Gel Technologies announces FDA approval of TWYNEO®. Sol-Gel Advanced Topical Therapy. July 27, 2021. Accessed August 20, 2021. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-announces-fda-approval-twyneor 3. Mayne Pharma; data on file. Clinical Study Report SGT-65-04; May 28, 2020. 4. Mayne Pharma; data on file. Clinical Study Report SGT-65-05; June 5, 2020.